Sarepta Therapeutics Set to Join S&P MidCap 400
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Goldman Sachs Reinstates Johnson & Johnson (JNJ) at Neutral
May 30, 2024 7:25 AM EDTGoldman Sachs analyst Chris Shibutani reinstates coverage on Johnson & Johnson (NYSE: JNJ) with a Neutral rating and a price target of $160.00.
The analyst comments "We reinstate a rating on JNJ at Neutral. Over the near term (2024/25) we expect that JNJ's revenue and earnings growth is likely to remain tethered at relatively modest low single-digit levels,... More
